1 mation, and another 3 of these 20 received a fibrinolytic agent.

2 nctive antithrombotic therapy, against other fibrinolytic agents, a placebo, or no treatment.

3 y randomised controlled trials that compared fibrinolytic agents as a reperfusion therapy in adult pa

4                          Patients received a fibrinolytic agent, aspirin, and when appropriate, hepar

5                                            A fibrinolytic agent consisting of a tissue-type plasminog

6 eads to faster artery-opening treatment with fibrinolytic agents, either in the pre-hospital setting

7 hrombolysis and the potential novel use as a fibrinolytic agent for thromboprophylaxis without bleedi

8                               Treatment with fibrinolytic agents has shown promise but remains of unp

9 e catalytic activation of plasmin, the major fibrinolytic agent in mammals.

10                       It is widely used as a fibrinolytic agent in thrombolytic therapy and it is als

11 b/IIIa receptor inhibitors with reduced-dose fibrinolytic agents in acute MI, with the goal of overco

12      Finally, a new class of directly acting fibrinolytic agents is available.

13                               Paradoxically, fibrinolytic agents may systemically activate platelets,

14 arin and was significantly attenuated by the fibrinolytic agent streptokinase.

15  an assay for the screening of potential pro-fibrinolytic agents that target PAI-1 inhibition in a hu

16  for simulating the effects of a more potent fibrinolytic agent through direct antithrombin therapy.

17                               An aerosolized fibrinolytic agent, tissue-type plasminogen activator, s

18                                   The use of fibrinolytic agents to prevent new thrombus formation is

19 e studies show the feasibility of delivering fibrinolytic agents to sites of incipient thrombus forma